跳至主要内容
临床试验/NCT03678584
NCT03678584已完成不适用

Chaetoglobosin A Supplementation to ICSI Handling Medium

Ibn Sina Hospital5 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2018年9月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
300
试验地点
5
主要终点
Oocyte Survival after ICSI

研究概览

简要总结

Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Chaetoglobosin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Chaetoglobosin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 42 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • All ICSI participants agreed

排除标准

  • 未提供

研究组 & 干预措施

Handling Medium Supplemented with Chaetoglobosin A

Experimental

干预措施: Medium Supplemented with Chaetoglobosin A (Other)

handling Medium as it is.

No Intervention

结局指标

主要结局

Oocyte Survival after ICSI

时间窗: two days

Survived oocytes per MII injected

次要结局

  • Rate of top-quality embryo(6 days of culture)
  • blastocyst formation and quality(6 days of culture)
  • Fertilization rate(6 days of culture)
  • Ongoing pregnancy rate(12 weeks)
  • blastocyst utilization rate(6 days of culture)
  • clinical pregnancy rate(7 weeks)
  • Implantation rate(7 weeks)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Muhammad Fawzy

IVF Lab Director

Ibn Sina Hospital

研究点 (5)

Loading locations...

相似试验